<?xml version="1.0" encoding="UTF-8"?>
<tei xmlns="http://www.tei-c.org/ns/1.0">
    <teiHeader>
        <fileDesc xml:id="_1"/>
        <encodingDesc>
            <appInfo>
                <application version="0.8.1-SNAPSHOT" ident="GROBID" when="2024-06-14T13:07+0000">
                    <ref target="https://github.com/kermitt2/grobid">A machine learning software for extracting information from scholarly documents</ref>
                </application>
            </appInfo>
        </encodingDesc>
    </teiHeader>
    <text xml:lang="en">
        <p>3. Risks and 12-month burdens of incident post-acute COVID-19 cardiovascular outcomes compared to contemporary control Outcome* Hazard Ratio (95% CI) † COVID-19 burden per 1000 persons at 12 months (95% CI) † Contemporary control burden per 1000 persons at 12 months (95% CI) † Absolute burden difference per 1000 persons at 12 months (95% CI) † COVID-19 vs Contemporary control Cerebrovascular3. Risks and 12-month burdens of incident post-acute COVID-19 cardiovascular outcomes compared to contemporary control Outcome* Hazard Ratio (95% CI) † COVID-19 burden per 1000 persons at 12 months (95% CI) † Contemporary control burden per 1000 persons at 12 months (95% CI) † Absolute burden difference per 1000 persons at 12 months (95% CI) † COVID-19 vs Contemporary control Cerebrovascular</p>
        <p>Any cardiovascular outcome 1.63 (1.59, 1.68) 121.60 (118.52, 124.76) 76.31 (76.08, 76.54) 45.29 (42.22, 48.45) *. Outcomes were ascertained from day 30 after the initial positive COVID-19 test result until end of follow up †. Adjustment through inverse probability weighting using predefined and algorithmically selected high-dimensional variables. CI, confidence interval; TIA, transient ischemic attack; MACE, major adverse cardiac events. 32 (162.78, 201.71) 137.93 (119.40, 158.31)Any cardiovascular outcome 1.63 (1.59, 1.68) 121.60 (118.52, 124.76) 76.31 (76.08, 76.54) 45.29 (42.22, 48.45) *. Outcomes were ascertained from day 30 after the initial positive COVID-19 test result until end of follow up †. Adjustment through inverse probability weighting using predefined and algorithmically selected high-dimensional variables. CI, confidence interval; TIA, transient ischemic attack; MACE, major adverse cardiac events. 32 (162.78, 201.71) 137.93 (119.40, 158.31)</p>
        <p>Non-hospitalized 1.35 (1.32,1.38) 105.38 (102.93,107.88) 79.21 (78.98,79.45) 26.16 (23.72,28.66) Hospitalized 3.32 (3.11,3.55) 239.78 (226.33,253.90) 160.57 (147.12,174.68Non-hospitalized 1.35 (1.32,1.38) 105.38 (102.93,107.88) 79.21 (78.98,79.45) 26.16 (23.72,28.66) Hospitalized 3.32 (3.11,3.55) 239.78 (226.33,253.90) 160.57 (147.12,174.68</p>
        <p>†. Data collected within one year before cohort enrollment std, standard deviation; BMI, body mass index; eGFR, estimated glomerular filtration rate.†. Data collected within one year before cohort enrollment std, standard deviation; BMI, body mass index; eGFR, estimated glomerular filtration rate.</p>
        <p>**</p>
        <p>Outcomes were ascertained from day 30 after the Influenza vaccination until end of follow up †. Adjustment through inverse probability weighting using predefined and algorithmically selected high-dimensional variables. CI, confidence interval; TIA, transient ischemic attack; MACE, major adverse cardiac events.Outcomes were ascertained from day 30 after the Influenza vaccination until end of follow up †. Adjustment through inverse probability weighting using predefined and algorithmically selected high-dimensional variables. CI, confidence interval; TIA, transient ischemic attack; MACE, major adverse cardiac events.</p>
    </text>
</tei>
